Accumulation of tissue-resident natural killer cells, innate lymphoid cells, and CD8⁺ T cells towards the center of human lung tumors

References

• Piet B, de BG, Smids-Dierdorp BS, van Dervan der LC, Remmerswaal EBM, von der TJ, van HJ, Eerenberg JP, ten BA, van Dervan der BW, et al. CD8+ T cells with an intraepithelial phenotype upregulate cytotoxic function upon influenza infection in human lung. J Clin Invest. 2011;121(6):2254–9. doi:10.1172/jci44675.
   PubMed Web of Science ®Google Scholar
• Marquardt N, Kekäläinen E, Chen P, Lourda M, Wilson JN, Scharenberg M, Bergman P, Al-Ameri M, Hård J, Mold JE, et al. Unique transcriptional and protein-expression signature in human lung tissue-resident NK cells. Nat Commun. 2019;10(1):3841. doi:10.1038/s41467-019-11632-9.
   PubMed Web of Science ®Google Scholar
• Gasteiger G, Fan X, Dikiy S, Lee SY, Rudensky AY. Tissue residency of innate lymphoid cells in lymphoid and nonlymphoid organs. Science. 2015;350(6263):981–985. doi:10.1126/science.aac9593.
   PubMed Web of Science ®Google Scholar
• Meininger I, Carrasco A, Rao A, Soini T, Kokkinou E, Mjösberg J. Tissue-specific features of innate lymphoid cells. Trends Immunol. 2020;41(10):902–917. doi:10.1016/j.it.2020.08.009.
   PubMed Web of Science ®Google Scholar
• Carrega P, Morandi B, Costa R, Frumento G, Forte G, Altavilla G, Ratto GB, Mingari MC, Moretta L, Ferlazzo G. Natural killer cells infiltrating human nonsmall-cell lung cancer are enriched in CD56 bright CD16(-) cells and display an impaired capability to kill tumor cells. Cancer. 2008;112(4):863–875. doi:10.1002/cncr.23239.
   PubMed Web of Science ®Google Scholar
• Platonova S, Cherfils-Vicini J, Damotte D, Crozet L, Vieillard V, Validire P, André P, Dieu-Nosjean M-C, Alifano M, Régnard J-F, et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res. 2011;71(16):5412–5422. doi:10.1158/0008-5472.can-10-4179.
   PubMed Web of Science ®Google Scholar
• Lavin Y, Kobayashi S, Leader A, Amir ED, Elefant N, Bigenwald C, Remark R, Sweeney R, Becker CD, Levine JH, et al. Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell. 2017;169(4):750–765.e17. doi:10.1016/j.cell.2017.04.014.
   PubMed Web of Science ®Google Scholar
• Russick J, Joubert P-E, Gillard-Bocquet M, Torset C, Meylan M, Petitprez F, Dragon-Durey M-A, Marmier S, Varthaman A, Josseaume N, et al. Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions. J ImmunoTher Cancer. 2020;8(2):e001054. doi:10.1136/jitc-2020-001054.
   PubMed Web of Science ®Google Scholar
• Trefny MP, Kaiser M, Stanczak MA, Herzig P, Savic S, Wiese M, Lardinois D, Läubli H, Uhlenbrock F, Zippelius A. PD-1+ natural killer cells in human non-small cell lung cancer can be activated by PD-1/PD-L1 blockade. Cancer Immunol Immunother. 2020;69(8):1505–1517. doi:10.1007/s00262-020-02558-z.
   PubMed Web of Science ®Google Scholar
• Carrega P, Loiacono F, Carlo ED, Scaramuccia A, Mora M, Conte R, Benelli R, Spaggiari GM, Cantoni C, Campana S, et al. NCR+ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures. Nat Commun. 2015;6(1):8280. doi:10.1038/ncomms9280.
   PubMedGoogle Scholar
• Koh J, Kim HY, Lee Y, Park IK, Kang CH, Kim YT, Kim J-E, Choi M, Lee W-W, Jeon YK, et al. IL23-producing human lung cancer cells promote tumor growth via conversion of innate lymphoid cell 1 (ILC1) into ILC3. Clin Cancer Res. 2019;25(13):4026–4037. doi:10.1158/1078-0432.ccr-18-3458.
   PubMed Web of Science ®Google Scholar
• Floc’h AL, Jalil A, Vergnon I, Chansac BLM, Lazar V, Bismuth G, Chouaib S, Mami-Chouaib F. Alpha E beta 7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis. J Exp Medicine. 2007;204(3):559–570. doi:10.1084/jem.20061524.
   PubMed Web of Science ®Google Scholar
• Ganesan A-P, Clarke J, Wood O, Garrido-Martin EM, Chee SJ, Mellows T, Samaniego-Castruita D, Singh D, Seumois G, Alzetani A, et al. Tissue-resident memory features are linked to the magnitude of cytotoxic T cell responses in human lung cancer. Nat Immunol. 2017;18(8):940–950. doi:10.1038/ni.3775.
   PubMed Web of Science ®Google Scholar
• Duhen T, Duhen R, Montler R, Moses J, Moudgil T, de MN, Goodall CP, Blair TC, Fox BA, McDermott JE, et al. Co-expression of CD39 and CD103 identifies tumor-reactive CD8 T cells in human solid tumors. Nat Commun. 2018;9(1):2724. doi:10.1038/s41467-018-05072-0.
   PubMed Web of Science ®Google Scholar
• Marquardt N, Kekäläinen E, Chen P, Kvedaraite E, Wilson JN, Ivarsson MA, Mjösberg J, Berglin L, Säfholm J, Manson ML, et al. Human lung natural killer cells are predominantly comprised of highly differentiated hypofunctional CD69 − CD56 dim cells. J Allergy Clin Immun. 2017;139(4):1321–1330.e4. doi:10.1016/j.jaci.2016.07.043.
   PubMed Web of Science ®Google Scholar
• Arenberg DA, Keane MP, DiGiovine B, Kunkel SL, Strom SRB, Burdick MD, Iannettoni MD, Strieter RM. Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines. Cancer Immunol Immunother. 2000;49(2):63–70. doi:10.1007/s002620050603.
   PubMed Web of Science ®Google Scholar
• Hu W, Liu Y, Zhou W, Si L, Ren L, Kalinichenko VV. CXCL16 and CXCR6 are coexpressed in human lung cancer in vivo and mediate the invasion of lung cancer cell lines in vitro. PLoS One. 2014;9(6):e99056. doi:10.1371/journal.pone.0099056.
   PubMed Web of Science ®Google Scholar
• House IG, Savas P, Lai J, Chen AXY, Oliver AJ, Teo ZL, Todd KL, Henderson MA, Giuffrida L, Petley EV, et al. Macrophage-derived CXCL9 and CXCL10 are required for antitumor immune responses following immune checkpoint blockade. Clin Cancer Res. 2020;26(2):487–504. doi:10.1158/1078-0432.ccr-19-1868.
   PubMed Web of Science ®Google Scholar
• Melaiu O, Lucarini V, Cifaldi L, Fruci D. Influence of the tumor microenvironment on NK cell function in solid tumors. Front Immunol. 2020;10:3038. doi:10.3389/fimmu.2019.03038.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Liu S, Zhang B, Qiao L, Zhang Y, Zhang Y. T cell dysfunction and exhaustion in cancer. Front Cell Dev Biol. 2020;8:17. doi:10.3389/fcell.2020.00017.
   PubMed Web of Science ®Google Scholar
• Niu C, Li M, Zhu S, Chen Y, Zhou L, Xu D, Xu J, Li Z, Li W, Cui J. PD-1-positive natural killer cells have a weaker antitumor function than that of PD-1-negative natural killer cells in lung cancer. Int J Med Sci. 2020;17(13):1964–1973. doi:10.7150/ijms.47701.
   PubMed Web of Science ®Google Scholar
• Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20(11):651–668. doi:10.1038/s41577-020-0306-5.
   PubMed Web of Science ®Google Scholar
• Cao Y, Wang X, Jin T, Tian Y, Dai C, Widarma C, Song R, Xu F. Immune checkpoint molecules in natural killer cells as potential targets for cancer immunotherapy. Sig Transduct Target Ther. 2020;5(1):250. doi:10.1038/s41392-020-00348-8.
   PubMed Web of Science ®Google Scholar
• Anderson AC, Joller N, Lag-3 KV. Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989–1004. doi:10.1016/j.immuni.2016.05.001.
   PubMed Web of Science ®Google Scholar
• Chauvin J-M, Zarour HM. TIGIT in cancer immunotherapy. J ImmunoTher Cancer. 2020;8(2):e000957. doi:10.1136/jitc-2020-000957.
   PubMed Web of Science ®Google Scholar
• Timperi E, Barnaba V. CD39 regulation and functions in T cells. Int J Mol Sci. 2021;22(15):8068. doi:10.3390/ijms22158068.
   PubMed Web of Science ®Google Scholar
• Allard D, Allard B, Stagg J. On the mechanism of anti-CD39 immune checkpoint therapy. J ImmunoTher Cancer. 2020;8(1):e000186. doi:10.1136/jitc-2019-000186.
   PubMed Web of Science ®Google Scholar
• Wendel M, Galani IE, Suri-Payer E, Cerwenka A. Natural killer cell accumulation in tumors is dependent on IFN-γ and CXCR3 ligands. Cancer Res. 2008;68(20):8437–8445. doi:10.1158/0008-5472.can-08-1440.
   PubMed Web of Science ®Google Scholar
• Gillard-Bocquet M, Caer C, Cagnard N, Crozet L, Perez M, Fridman WH, Sautès-Fridman C, Cremer I. Lung tumor microenvironment induces specific gene expression signature in intratumoral NK cells. Front Immunol. 2013;4:19. doi:10.3389/fimmu.2013.00019.
   PubMed Web of Science ®Google Scholar
• Pilato MD, Kfuri-Rubens R, Pruessmann JN, Ozga AJ, Messemaker M, Cadilha BL, Sivakumar R, Cianciaruso C, Warner RD, Marangoni F, et al. CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. Cell. 2021;184(17):4512–4530.e22. doi:10.1016/j.cell.2021.07.015.
   PubMed Web of Science ®Google Scholar
• Dangaj D, Bruand M, Grimm AJ, Ronet C, Barras D, Duttagupta PA, Lanitis E, Duraiswamy J, Tanyi JL, Benencia F, et al. Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors. Cancer Cell. 2019;35(6):885–900.e10. doi:10.1016/j.ccell.2019.05.004.
   PubMed Web of Science ®Google Scholar
• Moreno-Nieves UY, Tay JK, Saumyaa S, Horowitz NB, Shin JH, Mohammad IA, Luca B, Mundy DC, Gulati GS, Bedi N, et al. Landscape of innate lymphoid cells in human head and neck cancer reveals divergent NK cell states in the tumor microenvironment. Proc Natl Acad Sci USA. 2021;118(28):e2101169118. doi:10.1073/pnas.2101169118.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Li Y, Zhu B. T-cell exhaustion in the tumor microenvironment. Cell Death Disease. 2015;6(6):e1792. doi:10.1038/cddis.2015.162.
   PubMed Web of Science ®Google Scholar
• Okła K, Farber DL, Zou W. Tissue-resident memory T cells in tumor immunity and immunotherapy. J Exp Med. 2021;218(4):e20201605. doi:10.1084/jem.20201605.
   PubMed Web of Science ®Google Scholar
• Paul S, Kulkarni N, Shilpi, Lal G. Intratumoral natural killer cells show reduced effector and cytolytic properties and control the differentiation of effector Th1 cells. Oncoimmunology. 2016;5(12):e1235106. doi:10.1080/2162402x.2016.1235106.
   PubMed Web of Science ®Google Scholar
• Märkl F, Huynh D, Endres S, Kobold S. Utilizing chemokines in cancer immunotherapy. Trends Cancer. 2022;8(8):670–682. doi:10.1016/j.trecan.2022.04.001.
   PubMed Web of Science ®Google Scholar